×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Bristol Myers Squibb acquires MyoKardia Inc., a biomedical company co-founded by CU professor
University of Colorado Boulder
Bristol Myers Squibb acquires MyoKardia Inc., a biomedical company co-founded by CU professor ... Global biopharmaceutical company Bristol Myers...
41 months ago
With $350M payment to LianBio, Bristol Myers scoops up Asian rights to Camzyos
Fierce Pharma
Under a 2020 collaboration with MyoKardia, LianBio has held Asian rights to the potential blockbuster cardio drug mavacamten.
6 months ago
BMS, Avidity add another $100M to cardiovascular partnership
Fierce Biotech
Bristol Myers Squibb seems to have found a friend in Avidity Biosciences, as the two add a second link to a heart-focused research...
5 months ago
Bristol-Myers gets 'potentially revolutionary medicine' in MyoKardia deal, CEO says
CNBC
Bristol-Myers gets 'potentially revolutionary medicine' in MyoKardia deal, CEO says ... Bristol-Myers Squibb CEO Giovanni Caforio told CNBC's Jim...
43 months ago
Bristol Myers pours $100M into RNA drugs for cardiovascular diseases
Yahoo Finance
Tuesday's deal signals the pharmaceutical giant's confidence in Avidity Biosciences and its so-called antibody oligonucleotide conjugates.
5 months ago
BMS Strengthens Cardiovascular Business with $13.1 Billion MyoKardia Buyout
BioSpace
Only a year after buying cancer specialist Celgene for $74 billion, Bristol Myers Squibb announced it is buying cardiology company MyoKardia...
43 months ago
Bristol Myers expands heart drug business with $13 billion deal for MyoKardia
Reuters
Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments...
43 months ago
Comparing Cytokinetics' aficamten with BMS's Camzyos
BioCentury
Cytokinetics' recent Phase III data suggest aficamten might have a slight edge over Camzyos, the only drug on the market that addresses the...
4 months ago
MyoKardia Soars 59% After Bristol-Myers to Acquire It for $13 Billion
markets.businessinsider.com
MyoKardia, a clinical-stage biotechnology company based in Brisbane, California, soared 59% on Monday after it was announced that Bristol-Myers...
43 months ago
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
GlobeNewswire
SHANGHAI and PRINCETON, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing...
6 months ago